SCHEMBL17135331

SCHEMBL17135331

NS(=O)(=O)c1ncc(C(=O)N2CCC(c3ccc(F)cc3)CC2)c(N[C@H]2C[C@H]3CC[C@@H]2C3)c1Cl

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ JAK2 O60674 1/20 0.40
▸ JAK1 P23458 1/20 0.40
▸ JAK3 P52333 1/20 0.40
▸ CXCR1 P25024 1/20 0.38
▸ CXCR2 P25025 1/20 0.38
▸ ALDH1A1 P00352 2/20 0.36
▸ PARP10 Q53GL7 1/20 0.36
▸ FASN P49327 3/20 0.35
▸ TRPC6 Q9Y210 1/20 0.35
▸ EGLN1 Q9GZT9 1/20 0.34
▸ CA12 O43570 2/20 0.34
▸ CA1 P00915 2/20 0.34
▸ CA2 P00918 2/20 0.34
▸ CA9 Q16790 2/20 0.34
▸ CA7 P43166 1/20 0.34
▸ CA14 Q9ULX7 1/20 0.34
▸ PRSS12 P56730 1/20 0.34
▸ CNR2 P34972 1/20 0.34
▸ GABBR2 O75899 1/20 0.34
▸ GABBR1 Q9UBS5 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17135332 1.00 JAK2 (0.40) JAK2JAK1JAK3CXCR1CXCR2
SCHEMBL17134828 0.86 PARP10 (0.40) ALDH1A1PARP10FASNTRPC6EGLN1
SCHEMBL17134902 0.85 FASN (0.35) ALDH1A1PARP10FASNTRPC6EGLN1
SCHEMBL17134657 0.85 PARP10 (0.45) ALDH1A1PARP10FASNTRPC6EGLN1
SCHEMBL17135327 0.84 PARP10 (0.39) ALDH1A1PARP10FASNTRPC6EGLN1
SCHEMBL17135136 0.81 ALDH1A1 (0.38) ALDH1A1PARP10FASNEGLN1CA12
SCHEMBL17134610 0.81 EGLN1 (0.40) ALDH1A1PARP10FASNTRPC6EGLN1
SCHEMBL17134831 0.80 CCR1 (0.42) PARP10TRPC6EGLN1CA12CA1
SCHEMBL17135223 0.80 FASN (0.43) ALDH1A1PARP10FASNTRPC6EGLN1
SCHEMBL17134695 0.80 PARP10 (0.43) ALDH1A1PARP10FASNTRPC6EGLN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2927214-B1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND KYOWA HAKKO KIRIN CO LTD (JP) 2018-03-21 — — EP disclosed
US-9701689-B2 Substituted pyridines and pyridazines as CCR10 receptor inhibitors KYOWA HAKKO KIRIN CO., LTD. (JP) 2017-07-11 — — US disclosed
US-20150299214-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND KYOWA HAKKO KIRIN CO., LTD. (JP) 2015-10-22 — — US disclosed
EP-2927214-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND Kyowa Hakko Kirin Co., Ltd. (JP) 2015-10-07 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150299214-A1 NITROGEN-CONTAINING HETEROCYCLIC COMPOUND ARG1, H1-0, TYR JAK2 280/4885JAK1 595/4885JAK3 1319/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback